A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms ALT GIST
- 15 Jun 2019 Planned number of patients changed from 240 to 76.
- 15 Jun 2019 Planned End Date changed from 1 Dec 2020 to 31 Dec 2019.
- 15 Jun 2019 Status changed from recruiting to active, no longer recruiting.